Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168729 | 0.81 | MAPT (0.52) | MAPTLMNAALDH1A1KMT2AGAA | |
| SCHEMBL171043 | 0.73 | DGAT1 (0.44) | DGAT1MAPTMAPK1SMN1; SMN2LMNA | |
| SCHEMBL7421005 | 0.72 | MAPT (0.50) | MAPTMAPK1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL4399969 | 0.72 | MAPT (0.70) | MAPTMAPK1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL31639759 | 0.72 | DGAT1 (0.48) | DGAT1MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL18971917 | 0.69 | CYP1A2 (0.57) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL20794004 | 0.69 | MAPT (0.40) | DGAT1MAPTALDH1A1KMT2AGAA | |
| SCHEMBL8715790 | 0.69 | MAPT (0.47) | MAPTMAPK1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL7845711 | 0.68 | MAPT (0.50) | MAPTSMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL7417406 | 0.68 | ALDH1A1 (0.70) | MAPTMAPK1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885MAPT 137/4885MAPK1 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.